After almost 4 days of little or no action, the Nifty and Sensex are under selling pressure. A combination of factors is responsible for the selling pressure. However, there are some individual stocks that are seeing strong traction in a falling market. Some of the stocks are up as much as 14% in trade today.
Let’s take a look at the big movers and shakers in trade today
TCS
TCS is amongst the most prominent losers on the benchmark index. Both on Nifty and Sensex, the TCS share price took a significant battering. This is after the Q1 numbers failed to lift investor sentiment. While TCS Q1 profit came in above estimates, the revenue and EBIT margins declined. Most brokerage houses have cu the price target for the company due to a lack of growth visibility and no major growth driver for FY26. The TCS earnings also worried investors about how the rest of the IT sector stocks would perform in terms of earnings.
Glenmark
Glenmark is up a striking 14% after its US subsidiary, Ichnos Glenmark Innovation (IGI) and AbbVie announced an exclusive global $700 million licensing agreement for ISB 2001, a key cancer drug. Under the terms of the agreement, AbbVie will receive exclusive rights to develop, manufacture, and commercialise ISB 2001 across North America, Europe, Japan, and Greater China. Subject to regulatory clearance, IGI will receive an upfront payment of $700 million and is eligible to receive up to $1.225 billion in development, regulatory, and commercial milestone payments, along with tiered, double-digit royalties on net sales.
NTPC Green
The NTPC Green Energy share price is up 4% in trade today. In a report released recent, Jefferies has listed its parent firm NTPC as a value buy, and the brokerage firm mentioned that, “NTPC Green, implied valuation is 1.4x PB FY27E. Capacity ramp-up and medium-term double-digit EPS CAGR are key re-rating drivers.” The company’s capacity ramp-up is underway and is significantly ahead of target.
Max Healthcare
The share price of Max Healthcare is down 3% ahead of its Q1 earnings later this month. The hospital stock has delivered over 35% gains in 1 year. Mos brokerages are positive on the stock as Max Healthcare’s revenue mix remains well-balanced, with continued growth in institutional and international patient segments.
The company clocked a sharp increase in the share of institutional business in Q4FY25. This share is expected to “stabilise as higher-value payer segments expand. The short-term margin impact from new hospital ramp-ups is expected to ease as these facilities scale their operations gradually. Lucknow, Noida, and Nagpur are expected to see further profitability expansion, supported by higher occupancy rates and the introduction of new clinical programs,” highlighted Axis Securities.
BSE
The BSE share price is under significant selling pressure. It is one of the top midcap losers down nearly 4% in trade today. It is the top lower on the Nifty Midcap 100 Index as well as Nifty Midcap 150 Index. The stock has been under severe selling pressure in past week since SEBI’s ban on US trading giant, Jane Street. The share price is down 10% in last 5 trading sessions.